
Pfizer Halts Weight-Loss Pill Development After Liver Injury
Pfizer halted development of its experimental daily weight-loss pill, danuglipron, following a patient's potential liver injury in a trial. The patient's liver enzymes recovered, but the incident, coupled with previous setbacks, led Pfizer to discontinue the drug. While disappointed, Pfizer remains committed to its other weight-loss drug development...








